Overview / Abstract: |
Learning Objectives Upon completion of this activity, participants should be able to: Incorporate accumulated clinical evidence, current guidelines, and emerging new clinical data into individualized selection of DMTs for MS as part of a comprehensive approach to management that includes SDM with patients, ongoing monitoring, and DMT optimization |
Expiration |
Jul 25, 2020 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
Format |
Webinar / Webcast / Video |
Credits / Hours |
1.0 |
Accreditation |
ACCME, APCPE, ANCC |
Presenters / Authors / Faculty |
Scott D. Newsome, DO, MSCS, FAAN Robert K. Shin, MD, FANA, FAAN June Halper, MSN, APN-C, MSCN, FAAN, Laurie Scudder, DNP, NP |
Activity Specialities / Related Topics |
Neurology |
Sponsors / Supporters / Grant Providers |
Biogen, Celgene, Genentech, and Sanofi Genzyme. |
Keywords / Search Terms |
Relias LLC Multiple Sclerosis Free CE CME |